Fractyl racks up $57 mln Series C

By Iris Dorbian — 3 months ago

Waltham, Massachusetts-based Fractyl Laboratories Inc, which focuses on addressing metabolic diseases, has closed its Series C funding at $57 million. New investor Deerfield Management has joined Mithril, General Catalyst, Bessemer Venture Partners and Domain Associates in the round.

Continue

Syndax Pharmaceuticals racks up $80 mln Series C

By Iris Dorbian — 6 months ago

Waltham, Massachusetts-based Syndax Pharmaceuticals Inc, a biopharmaceutical company focused on treating cancer, has closed $80 million in Series C funding. Fidelity Management & Research Company and Delos Capital Fund LP led the round with participation from other investors that included EcoR1 Capital, OrbiMed, Jennison Associates (on behalf of certain clients), Tavistock Life Sciences, Arrowpoint Partners, Cormorant Asset Management, BioMed Ventures, Domain Associates, MPM Capital, RusnanoMedInvest and Forward Ventures.

Continue

Xagenic scores Series B funds

By Iris Dorbian — 7 months ago

Toronto-based molecular diagnostics company Xagenic has secured C$15 million in Series B funding. The investors included Domain Associates, CTI Life Sciences, BDC Capital and the Ontario Capital Growth Corporation.

Continue

Milestone Pharmaceuticals picks up $17 mln

By Iris Dorbian — 8 months ago

Canada-based Milestone Pharmaceuticals, a drug developer focused on cardiovascular diseases, has raised $17 million in Series B funding. Domain Associates led the round with participation from other investors that included Fonds de solidarité FTQ, Pappas Ventures, BDC Capital, GO Capital and iNovia Capital. In conjunction with the funding, Domain’s Debra Liebert has been added to Milestone’s board of directors.

Continue

VC-backed Glaukos Corp files for IPO

By Iris Dorbian — 9 months ago

Laguna Hills, California-based Glaukos Corporation, a developer of treatments for glaucoma, has filed for an IPO. The number of shares that will be sold as well as the IPO’s pricing terms have yet to be set. The company plans on trading the stock on the NYSE under the ticker symbol “GKOS.” J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co are serving as the lead underwriters. Glaukos’ backers include OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Domain Associates, Fjord Ventures, Montreaux Equity Partners and Versant Ventures

Continue

VC-backed aTyr Pharma rolls out IPO

By Iris Dorbian — 9 months ago

San Diego-based biotherapeutics company aTyr Pharma Inc has debuted its IPO after pricing its 5.36 million shares at $14 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “LIFE.” J.P. Morgan Securities LLC and Citigroup Global Markets are serving as the lead underwriters. The company’s backers include Alta Partners, Cardinal Partners, Domain Associates, Polaris Partners, Sofinnova Ventures, T. Rowe Price Associates Inc, Federated Investors Inc, Deerfield, Rock Springs Capital Management, EcoR1 Capital and Sphera Global Healthcare.

Continue

VC-backed aTyr files for IPO

By Iris Dorbian — 10 months ago

San Diego-based biotherapeutics company aTyr Pharma Inc has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on trading its stock on the NASDAQ under the ticker symbol “LIFE.” J.P. Morgan Securities LLC and Citigroup Global Markets Inc will serve as the lead underwriters. The company’s backers include Alta Partners, Cardinal Partners, Domain Associates, Polaris Partners, Sofinnova Ventures, T. Rowe Price Associates Inc, Federated Investors Inc, Deerfield, Rock Springs Capital Management, EcoR1 Capital and Sphera Global Healthcare.

Continue

Obalon Therapeutics nabs $30 mln

By Iris Dorbian — 1 year ago

San Diego-based Obalon Therapeutics, a developer of gastric balloon technology for weight loss therapy, has received $20 million in Series D funding and a $10 million loan from Square 1 Bank. The Series D investors included Axon Ventures, Mirae Asset Venture Investment, Striker Asia Opportunities Fund, Domain Associates, InterWest Partners and Okapi Venture Capital.

Continue

CoLucid Pharmaceuticals nabs $37.1 mln

By Iris Dorbian — 1 year ago

Durham, North Carolina-based CoLucid Pharmaceuticals, which develops oral lasmiditan that treats migraine headaches, has raised $37.1 million in Series C funding. TVM Capital Life Science led the round with participation from other investors Novo Ventures, Auriga Partners, Pappas Ventures, Domain Associates, Care Capital, Triathlon Medical Ventures and Pearl Street Ventures. Also, Dr. Luc Marengere of TVM Capital Life Science and Dr. Martin Edwards of Novo Ventures have been added to CoLucid’s board of directors.

Continue

BioNano Genomics scores $53 mln Series C

By Iris Dorbian — 1 year ago

San Diego-based BioNano Genomics, a provider of genome mapping, has closed $53 million in Series C financing. Legend Capital and Novartis Venture Fund led the round with participation from Federated Kaufmann Fund, Monashee Investment Management, Domain Associates, Battelle Ventures and Gund Investment Corp. In conjunction with the funding, Dr. Darren Cai of Legend Capital and Dr. Campbell Murray of Novartis Venture Fund have been added to BioNano’s board of directors.

Continue

Fractyl garners $40 mln Series C

By Iris Dorbian — 1 year ago

Fractyl Laboratories said Thursday that it has secured $40 million in Series C funding. Mithril led the round with participation from General Catalyst, Bessemer Venture Partners and Domain Associates. In conjunction with the funding, Ajay Royan, Mithril’s co-founder and managing general partner, has been added to the company’s board of directors. Based in Waltham, Mass., Fractyl is a developer of a device-based endoscopic procedure to treat Type 2 diabetes.

Continue

Epic Sciences picks up $30 mln Series C

By Iris Dorbian — 2 years ago

Epic Sciences said Wednesday that it has secured $30 million in Series C financing. The investors included RusnanoMedInvest, Arcus Ventures, Domain Associates, Roche Venture Fund and Pfizer Venture Investments. Based in San Diego, Calif., Epic is a biotech firm focused on cancer diagnostics.

Continue

VC-backed Otonomy files for IPO

By Iris Dorbian — 2 years ago

Otonomy said Monday that it has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. J.P. Morgan Securities and BofA Merrill Lynch are serving as the lead underwriters. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases. Its backers include Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners.

Continue

VC-backed ProteinSimple files for IPO

By Iris Dorbian — 2 years ago

ProteinSimple has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on listing the stock on the NASDAQ under the ticker symbol “PRTN.” JP Morgan and BofA Merill Lynch will serve as lead underwriters. Based in Santa Clara, Calif., ProteinSimple is a provider of protein analysis. Its backers include Essex Woodlands Health Ventures, Novo AS and Domain Associates.

Continue

Otonomy scores $49 mln Series D funds

By Iris Dorbian — 2 years ago

Otonomy said Wednesday that it has closed $49 million in Series D funding. The investors included Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases.

Continue

Sequent Medical rakes in $20 mln

By Iris Dorbian — 2 years ago

Sequent Medical said Tuesday that it has received $20 million in Series D financing. Previous backer Delphi Ventures led the round with participation from Domain Associates, US Venture Partners and Versant Ventures. Headquartered in Aliso Viejo, Calif., Sequent Medical is a medical-device company focused on catheter-based neurovascular technologies.

Continue